February 13, 2024 · Form 4 insider transaction
Gault Laura bought 11,250 shares of SAGE Therapeutics Holdings at $0.00 per share, a transaction worth N/A. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 2 days after the transaction.
Consists of shares of common stock issuable under 11,250 restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. These RSUs are scheduled to vest in equal annual installments over four years with the first installment vesting on February 13, 2025.; Reflects beneficial ownership balance which includes 227 shares purchased on December 29,2023 under the Sage Therapeutics, Inc. 2014 Employee Stock Purchase Plan.